Neurocrine Biosciences (NBIX) Gross Margin (2017 - 2026)
Neurocrine Biosciences (NBIX) posted quarterly Gross Margin of 97.58% for Q2 2026, down 92.0% year-over-year from 1219.76% in Q2 2025, and down 0.74% on a QoQ basis from 98.31% in Q1 2026.
Neurocrine Biosciences (NBIX) Gross Margin (2017 - 2026) Analysis & Trends
Neurocrine Biosciences has reported Gross Margin for 10 years, with the latest figure at 97.58% in Q2 2026.
- Gross Margin for Q2 2026 came in at 97.58%, down 92.0% year-over-year; the trailing twelve-month figure through Jun 2026 was 97.97% (down 57.0% YoY), and the FY2025 annual result was 98.18%, down 38.0% from the prior year.
- Gross Margin slipped to 97.58% in Q2 2026, from 98.31% in the prior quarter.
- Over five years, Gross Margin peaked at 98.71% in Q3 2024 and troughed at 76.0% in Q2 2022.
- A 5-year average of 96.98% and a median of 98.33% in 2023 frame the typical range for Gross Margin.
- The widest annual swing landed in 2022, when Gross Margin plunged 2293 bps; it then soared 2146 bps in 2023.
- A 5-year view of Gross Margin shows it stood at 98.13% in 2022, then advanced by 0 bps to 98.35% in 2023, then gained by 0 bps to 98.52% in 2024, then declined by 1 bps to 97.82% in 2025, then decreased by 0 bps to 97.58% in 2026.
- Per Business Quant data, the three most recent Gross Margin figures were 97.58% in Q2 2026, 98.31% in Q1 2026, and 97.82% in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.01 Bn | 39.35 Bn | 2.15 Bn | 51.98% |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | 42.63% |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 66.66% |
| 5 | United Therapeutics | 22.17 Bn | 19.51 Bn | 683.80 Mn | 87.30% |
| 6 | Viatris | 18.73 Bn | 17.85 Bn | 1.46 Bn | 38.77% |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | 97.58% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 58.33% |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - | - |
| 10 | Alkermes | 8.12 Bn | 7.46 Bn | 397.90 Mn | 80.22% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 97.58% |
| Mar 31, 2026 | 98.31% |
| Dec 31, 2025 | 97.82% |
| Sep 30, 2025 | 98.24% |
| Jun 30, 2025 | 98.36% |
| Mar 31, 2025 | 98.39% |
| Dec 31, 2024 | 98.52% |
| Sep 30, 2024 | 98.71% |
| Jun 30, 2024 | 98.44% |
| Mar 31, 2024 | 98.54% |
| Dec 31, 2023 | 98.35% |
| Sep 30, 2023 | 97.75% |
| Jun 30, 2023 | 97.46% |
| Mar 31, 2023 | 97.98% |
| Dec 31, 2022 | 98.13% |
| Sep 30, 2022 | 98.43% |
| Jun 30, 2022 | 76.00% |
| Mar 31, 2022 | 98.52% |
| Dec 31, 2021 | 98.69% |
| Sep 30, 2021 | 98.58% |